Systemic Amyloidosis Therapeutic Market Analysis

The Global Systemic Amyloidosis Therapeutic Market is estimated to be valued at USD 6.19 Bn in 2024 and is expected to reach USD 10.99 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.

The market has been witnessing positive trends in the recent past due to high prevalence of systemic amyloidosis across the globe and increasing research for developing novel therapeutics for the treatment of the disease. Development of targeted therapies holds promise for better management of systemic amyloidosis. Moreover, several pipeline drugs are under clinical trials that could potentially enter the market in the coming years. With increasing awareness about the disease and supportive government initiatives, the systemic amyloidosis therapeutic market is expected to witness significant growth over the forecast period. However, high cost of treatment and lack of effective treatment remain major challenges for the market.